Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospira’s Inflectra, EU’s First Biosimilar mAb, Will Challenge Skeptics

This article was originally published in The Pink Sheet Daily

Executive Summary

Hospira’s Inflectra becomes the first biosimilar monoclonal antibody to be authorized in Europe – but pricing and overcoming doctors’ skepticism looks like the key to real EU success.

You may also be interested in...



EU Demands Pfizer Offload Its Infliximab Biosimilar In Hospira Buy

Pfizer won EU antitrust approval for its plan to buy Hospira after promising to divest certain assets including its own biosimilar version of tumor necrosis factor inhibitor infliximab, to allay competition concerns. Still open are questions about possible buyers and what this means for competitors.

Biosimilars Missing In Action: FDA, Sponsors Quiet About Pending Applications

Approval of Sandoz's Zarxio aside, dearth of advisory committee meeting announcements and sponsors' reluctance to discuss status of 351(k) filings suggests regulatory road has not been smooth for some early biosimilar candidates.

J&J’s Gorsky Stands By Remicade Longevity As Biosimilar Impact Hits Europe

"We expect the biosimilar market to behave quite differently" than generics, CEO Alex Gorsky says even as international sales of Remicade fell 20% in the second quarter, though largely due to currency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel